MHC Molecules and Antigen Presentation

The immune system's ability to distinguish "self" from "nonself" hinges on a remarkable cellular communication system. At the heart of this system are Major Histocompatibility Complex (MHC) molecules, which function as molecular billboards, displaying peptide fragments for inspection by T lymphocytes. Understanding how MHC class I and class II molecules acquire and present different types of antigens is fundamental to immunology, explaining everything from viral immunity to organ transplant rejection and autoimmune disease.

The MHC: A Genetic Locus of Immune Recognition

The Major Histocompatibility Complex (MHC) is a large gene cluster found in all vertebrates; in humans, it is specifically called the Human Leukocyte Antigen (HLA) complex. These genes are the most polymorphic in the human genome, meaning they have an enormous number of different alleles within the population. This MHC diversity is evolutionarily advantageous, as it ensures that at least some individuals in a population will possess MHC molecules capable of presenting peptides from a novel pathogen, safeguarding the species from total wipeout by a single disease.

The proteins encoded by these genes are divided into two main functional classes: MHC class I and MHC class II. Their core function is identical—to bind peptide fragments and present them on the cell surface for T cells to "read." However, their source of peptides, the T cells they engage, and their cellular expression patterns are critically different. This division of labor orchestrates the two major arms of adaptive immunity: the elimination of intracellular threats (like viruses) and the coordination of responses against extracellular threats (like bacteria).

MHC Class I: The Sentinel of Intracellular Space

MHC class I molecules are expressed on the surface of virtually all nucleated cells in the body. Their job is to sample the interior of the cell and report on its contents to the immune system. They primarily present peptides derived from proteins synthesized within the cell. This includes normal self-proteins, viral proteins, and proteins from intracellular bacteria or mutated cancer antigens.

The pathway begins in the cytosol. Cellular proteins are constantly being degraded by a large multi-subunit protease called the proteasome. The resulting peptide fragments are then transported into the endoplasmic reticulum (ER) by a specialized transporter associated with antigen processing (TAP). Inside the ER, MHC class I alpha chains assemble with a protein called beta-2-microglobulin. This complex binds a peptide of typically 8–10 amino acids in length. A properly loaded, stable MHC I-peptide complex is then released from the ER, travels through the Golgi apparatus, and is displayed on the cell surface.

Here, it is scrutinized by CD8+ cytotoxic T cells (also called cytotoxic T lymphocytes, or CTLs). These T cells express a co-receptor protein called CD8, which binds to the invariant portion of the MHC class I molecule. If the T cell receptor (TCR) on a CD8+ T cell recognizes the presented peptide as foreign (e.g., viral), the T cell becomes activated. It then executes its lethal function, destroying the infected or abnormal cell by inducing apoptosis, thereby halting the production of more pathogen.

MHC Class II: The Commanders of the Extracellular Front

MHC class II molecules have a more restricted expression profile. They are constitutively expressed primarily on professional antigen-presenting cells (APCs), which include dendritic cells, macrophages, and B cells. Their specialized role is to sample the extracellular environment. APCs ingest pathogens, bacterial toxins, or other foreign material from outside the cell through phagocytosis or receptor-mediated endocytosis.

The internalized material is enclosed in a vesicle that fuses with a lysosome, creating a phagolysosome where the antigens are degraded into peptides. Meanwhile, MHC class II molecules are assembled in the ER with a temporary "cap" called the invariant chain (Ii), which blocks the peptide-binding groove and prevents it from loading with intracellular peptides. The MHC II-invariant chain complex is routed to the phagolysosome. Here, the invariant chain is degraded, leaving a small fragment called CLIP in the binding groove. A chaperone protein called HLA-DM then facilitates the removal of CLIP and its replacement with a peptide fragment derived from the extracellular antigen, typically 13–18 amino acids long. The loaded MHC II molecule is then transported to the cell surface.

On the surface, MHC II presents its peptide to CD4+ helper T cells. The CD4 co-receptor binds to the MHC class II molecule. Recognition of a foreign peptide by the TCR of a CD4+ T cell activates it. These helper T cells do not kill directly. Instead, they secrete cytokines that orchestrate the entire immune response: activating macrophages, helping B cells produce antibodies, and recruiting other immune cells to the site of infection. They are the master regulators of the adaptive immune system.

Cross-Presentation and the Critical Role of Dendritic Cells

A crucial exception to the standard pathways is a process called cross-presentation. Certain APCs, most notably dendritic cells, can sometimes present exogenous (extracellular) antigens on MHC class I molecules. This is vital for initiating CD8+ T cell responses against viruses or tumors that do not directly infect the dendritic cell itself. The dendritic cell can phagocytose a dead, virus-infected cell, process the viral antigens, and load them onto its own MHC I molecules via a specialized cytosolic pathway. It can then travel to a lymph node and present this viral peptide to naïve CD8+ T cells, priming them for action. This makes dendritic cells the most potent APC, uniquely capable of activating both naïve CD4+ and CD8+ T cells.

Clinical and Genetic Implications of MHC

The principles of MHC function have direct and profound clinical consequences. The high degree of MHC polymorphism is a double-edged sword. While it protects populations, it makes finding immunologically compatible organ donors difficult. Transplant rejection occurs because the recipient's T cells recognize the donor's MHC molecules as foreign, a phenomenon called allorecognition.

Furthermore, specific MHC alleles are statistically associated with an increased risk of developing certain autoimmune diseases. For example, HLA-B27 is strongly linked to ankylosing spondylitis, and specific HLA-DR/DQ alleles are linked to type 1 diabetes and rheumatoid arthritis. The prevailing theory is that these MHC molecules may inadvertently present self-peptides in a way that activates autoreactive T cells.

For the MCAT, it is essential to connect this knowledge to other disciplines. In genetics, understand haplotype inheritance and linkage disequilibrium. In sociology, the concept of MHC diversity influencing mate selection (via olfaction) touches on evolutionary psychology. In biochemistry, visualize the peptide-binding groove as a specific three-dimensional structure where anchor residues of the peptide interact.

Common Pitfalls

1. Confusing Cellular Expression: A classic trap is misremembering which cells express which MHC class. Remember: MHC I is on all nucleated cells (so not on mature red blood cells). MHC II is primarily on professional APCs (dendritic cells, macrophages, B cells). Some cells, like thymic epithelial cells or activated T cells, can inductibly express MHC II, but the core rule is essential.

1. Mixing Up Antigen Source and T Cell Type: It is easy to conflate the pathways. Use the mnemonic: "1 for 8, 2 for 4." MHC class I (1) presents endogenous (intracellular) peptides to CD8+ T cells. MHC class II (2) presents exogenous (extracellular) peptides to CD4+ T cells. Getting this relationship backwards will lead to incorrect answers about immune function.

1. Overlooking the Role of Co-receptors: The interaction is not just TCR-peptide/MHC. The CD8 or CD4 co-receptor is essential for stable binding and proper T cell signaling. CD8 binds to MHC I, and CD4 binds to MHC II. This is a key mechanism for ensuring that CD8+ T cells only respond to MHC I presentations (and thus intracellular threats) and CD4+ T cells only respond to MHC II (extracellular coordination).

1. Forgetting the "Why" of Polymorphism: Don't just memorize that MHC is polymorphic. Understand the evolutionary driver: it provides a survival advantage at the population level. If a new pathogen emerges, someone in the population will likely have an MHC allele that can present its peptides, allowing an immune response to develop.

Summary

• MHC class I molecules are expressed on all nucleated cells. They present peptides from intracellular proteins (e.g., viral or self) to CD8+ cytotoxic T cells, which then destroy the infected or abnormal cell.
• MHC class II molecules are expressed on professional antigen-presenting cells (APCs). They present peptides from extracellular antigens to CD4+ helper T cells, which then orchestrate and regulate the broader immune response.
• MHC diversity (polymorphism) within a population is critical for survival, as it ensures wide pathogen recognition capabilities, but it is also the primary cause of organ transplant rejection and is linked to autoimmune disease susceptibility.
• Dendritic cells are the most potent APCs, crucial for initiating T cell responses, and can perform cross-presentation (loading exogenous antigens onto MHC I).
• The strict pairing—MHC I/CD8+ T cells for intracellular threats and MHC II/CD4+ T cells for extracellular threats—forms the fundamental framework of adaptive cellular immunity.